| Identification | Back Directory | [Name]
Benzenesulfonamide, 3-(butylamino)-5-(4,5-dihydro-4-phenyl-5-thioxo-1H-1,2,4-triazol-3-yl)-2-phenoxy- | [CAS]
2417995-08-3 | [Synonyms]
COX-2-IN-23
Benzenesulfonamide, 3-(butylamino)-5-(4,5-dihydro-4-phenyl-5-thioxo-1H-1,2,4-triazol-3-yl)-2-phenoxy- | [Molecular Formula]
C24H25N5O3S2 | [MOL File]
2417995-08-3.mol | [Molecular Weight]
495.62 |
| Hazard Information | Back Directory | [Uses]
COX-2-IN-23 (compound 9a) is a selective COX-2 inhibitor with IC50 values of 0.28 and 20.14 μM for COX-2 and COX-1. COX-2-IN-23 has anti-inflammatory activity and low ulcerogenic activity. | [in vivo]
COX-2-IN-23 (compound 9a) (9 mg/kg; a single i.p.; 0-4 hours) exhibits anti-inflammatory activities and lowest incidence of pepticulcer[1]. | Animal Model: | Mature male albino rats[1] | | Dosage: | 9 mg/kg | | Administration: | Intraperitoneal injection; 0, 1, 2, 3 and 4 hours. | | Result: | Had similar ulcerogenic activity to celecoxib. |
| [IC 50]
COX-2: 0.28 μM (IC50); COX-1: 20.14 μM (IC50) | [References]
[1] Ibrahim TS, et al. Design, synthesis, and pharmacological evaluation of novel and selective COX-2 inhibitors based on bumetanide scaffold. Bioorg Chem. 2020 Jul;100:103878. DOI:10.1016/j.bioorg.2020.103878 |
|
|